Hologic initiated with an Overweight at Stephens

Stephens initiated coverage of Hologic with an Overweight rating and $87 price target. Hologic is “a leader in women’s health with a portfolio of products that have become the gold-standard for care,” the analyst tells investors. The company’s scaled installed base and stronger balance sheet after emerging from the pandemic leaves it well-positioned to execute on near-term targets and fuel long-term growth, says the analyst, who thinks 5%-7% near term growth “seems achievable.”